{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:17:43Z","timestamp":1783523863236,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08457-8","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:57:08Z","timestamp":1781863028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel Tie2xVEGF bispecific antibody fusion demonstrates enhanced therapeutic efficacy through direct Tie2 activation and VEGF neutralization"],"prefix":"10.1186","volume":"24","author":[{"given":"Min-Gi","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hoi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Injune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Guen","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Gwang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyeop","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7984-7305","authenticated-orcid":false,"given":"Nam-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"8457_CR1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857\u201367.","journal-title":"Drug Des Devel Ther"},{"key":"8457_CR2","doi-asserted-by":"publisher","unstructured":"Chen R, Zhu J, Hu J, Li X. Antiangiogenic therapy for ocular diseases: current status and challenges. MedComm \u2013 Future Med. 2023;2(1):e33. https:\/\/doi.org\/10.1002\/mef2.33.","DOI":"10.1002\/mef2.33"},{"key":"8457_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_78","volume":"242","author":"YM Paulus","year":"2017","unstructured":"Paulus YM, Sodhi A. Anti-angiogenic therapy for retinal disease. Handb Exp Pharmacol. 2017;242:271\u2013307.","journal-title":"Handb Exp Pharmacol"},{"issue":"14","key":"8457_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.14.26","volume":"62","author":"PA Campochiaro","year":"2021","unstructured":"Campochiaro PA. Retinal and choroidal vascular diseases: past, present, and Future: the 2021 proctor lecture. Invest. Ophthalmol. Vis. Sci. 2021;62(14):26. https:\/\/doi.org\/10.1167\/iovs.62.14.26.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"8457_CR5","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.2147\/DDDT.S383101","volume":"16","author":"M Xu","year":"2022","unstructured":"Xu M, Fan R, Fan X, Shao Y, Li X. Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis. DDDT. 2022;16:3241\u201362. https:\/\/doi.org\/10.2147\/DDDT.S383101.","journal-title":"DDDT"},{"key":"8457_CR6","doi-asserted-by":"publisher","unstructured":"Fu Y, Zhang Z, Webster KA, Paulus YM. Treatment strategies for anti-VEGF Resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization. Biomolecules. 2024;14(3):252. https:\/\/doi.org\/10.3390\/biom14030252.","DOI":"10.3390\/biom14030252"},{"issue":"1","key":"8457_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","volume":"6","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Heier JS, Do DV, Mirando AC, Pandey NB, Sheng H, et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retin Vitr. 2020;6(1):48. https:\/\/doi.org\/10.1186\/s40942-020-00250-z.","journal-title":"Int J Retin Vitr"},{"issue":"5","key":"8457_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cells10051049","volume":"10","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP. Anti-VEGF-Resistant retinal diseases: a review of the latest treatment options. Cells. 2021;10(5):10. https:\/\/doi.org\/10.3390\/cells10051049.","journal-title":"Cells"},{"issue":"5","key":"8457_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35(5):1305\u201316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x.","journal-title":"Eye (Lond)"},{"issue":"1","key":"8457_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133. https:\/\/doi.org\/10.1186\/s12967-023-03937-7.","journal-title":"J Transl Med"},{"issue":"1","key":"8457_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. The Angiopoietin\/Tie pathway in retinal vascular diseases: a review. Retina. 2021;41(1):1\u201319. https:\/\/doi.org\/10.1097\/IAE.0000000000003003.","journal-title":"Retina"},{"issue":"10","key":"8457_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jcm13102778","volume":"13","author":"G Chen-Li","year":"2024","unstructured":"Chen-Li G, Martinez-Archer R, Coghi A, Roca JA, Rodriguez FJ, Acaba-Berrocal L, et al. Beyond VEGF: angiopoietin\u2013Tie signaling pathway in diabetic retinopathy. JCM. 2024;13(10):13. https:\/\/doi.org\/10.3390\/jcm13102778.","journal-title":"JCM"},{"issue":"1","key":"8457_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12967-024-05441-y","volume":"22","author":"L Sha","year":"2024","unstructured":"Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y. Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med. 2024;22(1):898. https:\/\/doi.org\/10.1186\/s12967-024-05441-y.","journal-title":"J Transl Med"},{"key":"8457_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.11.008","volume":"171","author":"D Ferland-McCollough","year":"2017","unstructured":"Ferland-McCollough D, Slater S, Richard J, Reni C, Mangialardi G. Pericytes, an overlooked player in vascular pathobiology. Pharmacol Ther. 2017;171:30\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.008.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"8457_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CMG, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388. https:\/\/doi.org\/10.15252\/emmm.201505889.","journal-title":"EMBO Mol Med"},{"issue":"10326","key":"8457_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"key":"8457_CR17","doi-asserted-by":"publisher","unstructured":"Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, et al. Angiopoietin-1 guides directional angiogenesis through integrin \u03b1 v \u03b2 5 signaling for recovery of ischemic retinopathy. Sci Transl Med. 2013;5(203):203ra127. https:\/\/doi.org\/10.1126\/scitranslmed.3006666.","DOI":"10.1126\/scitranslmed.3006666"},{"issue":"4","key":"8457_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1167\/iovs.14-13897","volume":"55","author":"J Lee","year":"2014","unstructured":"Lee J, Park DY, Park DY, Park I, Chang W, Nakaoka Y, et al. Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest. Ophthalmol. Vis. Sci. 2014;55(4):2191\u201399. https:\/\/doi.org\/10.1167\/iovs.14-13897.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"issue":"15","key":"8457_CR19","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1073\/pnas.0307575101","volume":"101","author":"CH Cho","year":"2004","unstructured":"Cho CH, Kammerer RA, Lee HJ, Yasunaga K, Kim KT, Choi HH, et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101(15):5553\u201358. https:\/\/doi.org\/10.1073\/pnas.0307575101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8457_CR20","doi-asserted-by":"publisher","unstructured":"Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med. 2021;13(7):e08253. https:\/\/doi.org\/10.15252\/emmm.201708253.","DOI":"10.15252\/emmm.201708253"},{"issue":"9","key":"8457_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin\u2013TIE pathway. Nat Rev Drug Discov. 2017;16(9):635\u201361. https:\/\/doi.org\/10.1038\/nrd.2016.278.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"8457_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.11.10.27","volume":"11","author":"NJ Agard","year":"2022","unstructured":"Agard NJ, Zhang G, Ridgeway J, Dicara DM, Chu PY, Ohri R, et al. Direct Tie2 agonists stabilize vasculature for the treatment of diabetic macular Edema. Trans. Vis. Sci. Tech. 2022;11(10):27. https:\/\/doi.org\/10.1167\/tvst.11.10.27.","journal-title":"Trans. Vis. Sci. Tech"},{"issue":"1","key":"8457_CR23","doi-asserted-by":"publisher","first-page":"14021","DOI":"10.1038\/s41598-021-93660-4","volume":"11","author":"Y Koya","year":"2021","unstructured":"Koya Y, Nara H, Yagi S, Ueno C, Kamohara M. An engineered tetra-valent antibody fully activates the Tie2 receptor with comparable potency to its natural ligand angiopoietin-1. Sci Rep. 2021;11(1):14021. https:\/\/doi.org\/10.1038\/s41598-021-93660-4.","journal-title":"Sci Rep"},{"issue":"1","key":"8457_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s12276-024-01373-1","volume":"57","author":"FY Liu","year":"2025","unstructured":"Liu FY, Cho YL, Fridayana FR, Niloofar L, Vo MN, Huang Y, et al. MT-100, a human Tie2-agonistic antibody, improves penile neurovasculature in diabetic mice via the novel target Srpx2. Exp Mol Med. 2025;57(1):104\u201317. https:\/\/doi.org\/10.1038\/s12276-024-01373-1.","journal-title":"Exp Mol Med"},{"key":"8457_CR25","doi-asserted-by":"publisher","unstructured":"Ablooglu AJ, Desai A, Yoo JS, Park CH, Lee EA, Kim BY, et al. A ligand-independent Tie2-activating antibody reduces vascular leakage in models of Clarkson disease. Sci Adv. 2023;9(46):eadi 1394. https:\/\/doi.org\/10.1126\/sciadv.adi1394.","DOI":"10.1126\/sciadv.adi1394"},{"issue":"2","key":"8457_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s12276-023-00939-9","volume":"55","author":"E Lee","year":"2023","unstructured":"Lee E, Lee EA, Kong E, Chon H, Llaiqui-Condori M, Park CH, et al. An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Exp Mol Med. 2023;55(2):470\u201384. https:\/\/doi.org\/10.1038\/s12276-023-00939-9.","journal-title":"Exp Mol Med"},{"key":"8457_CR27","first-page":"61","volume":"2018","author":"NK Lee","year":"1701","unstructured":"Lee NK, Bidlingmaier S, Su Y, Liu B. Modular construction of large non-immune human antibody phage-display libraries from variable heavy and light chain gene cassettes. Methods Mol Biol. 2018;1701;2018:61\u201382.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"8457_CR28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1074\/jbc.M508199200","volume":"281","author":"WC Liang","year":"2006","unstructured":"Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem. 2006;281(2):951\u201361. https:\/\/doi.org\/10.1074\/jbc.M508199200.","journal-title":"J Biol Chem"},{"issue":"1","key":"8457_CR29","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1038\/s41467-021-26620-1","volume":"12","author":"G Jo","year":"2021","unstructured":"Jo G, Bae J, Hong HJ, Han AR, Kim DK, Hong SP, et al. Structural insights into the clustering and activation of Tie2 receptor mediated by Tie2 agonistic antibody. Nat Commun. 2021;12(1):6287. https:\/\/doi.org\/10.1038\/s41467-021-26620-1.","journal-title":"Nat Commun"},{"issue":"11","key":"8457_CR30","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1161\/ATVBAHA.118.309669","volume":"38","author":"S Payne","year":"2018","unstructured":"Payne S, De Val S, Neal A. Endothelial-specific cre mouse models. ATVB. 2018;38(11):2550\u201361. https:\/\/doi.org\/10.1161\/ATVBAHA.118.309669.","journal-title":"ATVB"},{"issue":"17","key":"8457_CR31","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1073\/pnas.1616166114","volume":"114","author":"VM Leppanen","year":"2017","unstructured":"Leppanen VM, Saharinen P, Alitalo K. Structural basis of Tie2 activation and Tie2\/Tie1 heterodimerization. Proc Natl Acad Sci USA. 2017;114(17):4376\u201381. https:\/\/doi.org\/10.1073\/pnas.1616166114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"8457_CR32","doi-asserted-by":"publisher","first-page":"100798","DOI":"10.1016\/j.xops.2025.100798","volume":"5","author":"U Chakravarthy","year":"2025","unstructured":"Chakravarthy U, Chaudhary V, Sadda SR, Tan CS, Vujosevic S, Fauser S, et al. Effect of Faricimab versus Aflibercept on Hyperreflective foci in patients with diabetic macular Edema from the YOSEMITE\/RHINE trials. Ophthalmol Sci. 2025;5(5):100798. https:\/\/doi.org\/10.1016\/j.xops.2025.100798.","journal-title":"Ophthalmol Sci"},{"issue":"6","key":"8457_CR33","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular Edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026.","journal-title":"Ophthalmology"},{"issue":"10326","key":"8457_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet"},{"issue":"18","key":"8457_CR35","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond). 2024;38(18):3569\u201377. https:\/\/doi.org\/10.1038\/s41433-024-03364-y.","journal-title":"Eye (Lond)"},{"key":"8457_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2025.08.034","volume":"280","author":"C Zhang","year":"2025","unstructured":"Zhang C, AbouKasm G, Lai DA, Leung N, Zhu D, Albini TA, et al. Clinical efficacy of switching to Faricimab in treatment Resistant neovascular age-related macular degeneration: systematic review and meta-analysis. Am J Ophthalmol. 2025;280:248\u201366. https:\/\/doi.org\/10.1016\/j.ajo.2025.08.034.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"8457_CR37","doi-asserted-by":"publisher","first-page":"30699","DOI":"10.1038\/s41598-025-15194-3","volume":"15","author":"M Saito","year":"2025","unstructured":"Saito M, Imaizumi K. Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration. Sci Rep. 2025;15(1):30699. https:\/\/doi.org\/10.1038\/s41598-025-15194-3.","journal-title":"Sci Rep"},{"issue":"12","key":"8457_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1167\/tvst.13.12.35","volume":"13","author":"M Shimura","year":"2024","unstructured":"Shimura M, Sasaki S, Nonaka R, Kashiwagi I, Yasuda K, Noma H, et al. Changes in aqueous angiopoietin-1\/2 concentrations during the induction phase of intravitreal Faricimab injections for diabetic macular Edema. Trans. Vis. Sci. Tech. 2024;13(12):35. https:\/\/doi.org\/10.1167\/tvst.13.12.35.","journal-title":"Trans. Vis. Sci. Tech"},{"key":"8457_CR39","unstructured":"Clinicaltrials.gov. A study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of RO7446603 administered alone or in combination with Aflibercept or Faricimab in participants with diabetic macular Edema (THAMES). Clinicaltrials. Gov. 01"},{"key":"8457_CR40","unstructured":"Roche and Genentech. A phase 1 study to evaluate the Tie2 agonist RO7446603 (RG6351), alone or in combination with aflibercept 2 mg or faricimab 6 mg, in diabetic macular edema https:\/\/medically.gene.com\/global\/en\/unrestricted\/ophthalmology\/ASRS-2025\/asrs-2025-presentation-brown-a-phase-1-study-to-evaluat.html"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08457-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:38:59Z","timestamp":1783521539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08457-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8457"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08457-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Asan Medical Center, Seoul, Republic of Korea (Approval No. #2024\u201330-057) and conducted in accordance with the ARRIVE guidelines and institutional ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.-K. Min, D. G. Lee, and N.-K. Lee are the inventors of MT-101 and MT-103, and J.-K. Min and N.-K. Lee are founders and stockholders of MabTics Co., Ltd., which has the right to use MT-101 and MT-103. The remaining authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"872"}}